On April 15, 2024, Outlook Therapeutics, Inc. closed the transaction. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | +1.65% | +7.67% | +1.52% |
May. 21 | CoStar Group has room for expansion | |
May. 16 | Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.52% | 187M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.32% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC